toremifene
Selected indexed studies
- Toremifene. (IARC Monogr Eval Carcinog Risks Hum, 1996) [PMID:9097128]
- Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. (Drugs Aging, 1997) [PMID:9342556]
- Toremifene: an evaluation of its safety profile. (Breast, 2006) [PMID:16289904]
_Worker-drafted node — pending editorial review._
Connections
toremifene is a side effect of
Sources
- Toremifene. (1996) pubmed
- Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. (1997) pubmed
- Toremifene: an evaluation of its safety profile. (2006) pubmed
- Toremifene for breast cancer: a review of 20 years of data. (2014) pubmed
- Introduction to toremifene. (1990) pubmed
- Clinical pharmacokinetics of toremifene. (2000) pubmed
- Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. (2011) pubmed
- Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. (1997) pubmed
- Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. (2006) pubmed
- Toremifene versus tamoxifen for advanced breast cancer. (2012) pubmed